Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Medical Oncology
•
Hematology
•
Internal Medicine
Would you use methotrexate to treat a small T-LGL clone (<650 cells/m3), with mild pancytopenia, and associated autoimmune disease such as systemic sclerosis?
Would a better alternative be consideration of a clinical trial with ruxolitinib?
Related Questions
Given the data from SWOG 1826 suggesting that Nivo-AVD is likely the preferred regimen for advanced Hodgkin lymphoma patients, are there scenarios where alternative regimens may still be preferred?
If a bone marrow biopsy reveals mast cell leukemia, would you consider treating with avapritinib?
How do you manage high-risk MDS IB2 patients on HMA and venetoclax who develop an acute stroke requiring antiplatelet therapy?
How do you approach second-line options for relapsed myeloma after front-line quadruplet therapy?
How would you counsel patients with personal or family histories of autoimmune disease on immune checkpoint inhibitor therapy for Hodgkin lymphoma?
How does one interpret an SPEP showing potentially obscured but non-quantifiable M-spike however an IFE showing monoclonal protein?
How do you monitor multiple myeloma in patients receiving dialysis?
Is there any indication for IVIG in immunocompromised patients with only decreased IgM and/or IgA levels?
How do you manage anticoagulation in a patient with DVT from likely malignant mechanical obstruction?
What is your approach to management of relapsed/refractory T-cell prolymphocytic leukemia (T-PLL)?